Summarizing our findings, they corroborate previous results, indicating the importance of tumor infiltration by CD8+ T lymphocytes, PD-1+ and PD-L1+ cells, as well as immune cell subsets that are less frequently studied, such as CD45RO+ memory T cells, FOXP3+ regulatory T cells, CD103+ tissue-resident T cells, CD20+ B lymphocytes, in the efficacy of PD-1 blocking therapy. The gene discussed is FOXP3; the disease is neoplasm.